📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 07-31 05:29:46时区推断·⟳ 抓取 07-31 05:32:22·⚡ 决策 08-01 08:13:22 +1d02h·87.5 天前
史赛克二季度业绩小幅超预期但最大分部收入不及预期，盘后下跌
收入和调整后EPS均小幅高于预期，但最大收入分部 Medical Surgery and Neurotechnology 销售额低于 LSEG 预期。
📄 原文Reuters↗ 原文
U.S. medical device maker Stryker (SYK.N) on Thursday beat Wall Street estimates for second-quarter results, aided by …
不做 史赛克（SYK.US）
同一二季度业绩催化已在内部处理过，且当前已过美股一个完整交易日；事件本身正负混合，剩余做多或做空edge不足，不重复出卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 high · price-in 风险 high ↗
关键理由
- 收入和调整后EPS均小幅高于预期，但最大收入分部 Medical Surgery and Neurotechnology 销售额低于 LSEG 预期。
- 全年调整后EPS指引只是收窄区间且低端小幅上调，不构成新的强负面或强正面指引变化。
- 查重命中同一二季度业绩催化已被系统处理，且当前已过美股一个完整交易日，剩余短线edge不足。
主要风险
- 若后续卖方继续下修 Medical Surgery and Neurotechnology 增速假设，史赛克仍可能承压。
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,535 字
U.S. medical device maker Stryker (SYK.N) on Thursday beat Wall Street estimates for second-quarter results, aided by strong demand for its implants and devices used in complex procedures ranging from spinal to orthopedic surgeries.
However, the company's shares fell 9% in extended trading after the Michigan-based firm missed analysts' estimates for medical surgery and neurotechnology sales in the quarter, its largest revenue-generating segment.
Here are the details:
The company, which makes joint replacements and medical implants used to repair broken bones, narrowed its forecast for adjusted annual profit to between $14.95 and $15.10 per share, from its prior range of $14.90 to $15.10 per share.
Stryker's rivals in the orthopedics market include Zimmer Biomet (ZBH.N) and healthcare conglomerate Johnson & Johnson (JNJ.N), where the companies jostle for market share across multiple segments such as hip and knee replacements, trauma and sports medicine.
Sales at Stryker's medical surgery and neurotechnology unit, rose 9.7% to $3.6 billion in the reported quarter, but missed analysts' estimates of $3.72 billion, according to data compiled by LSEG.
The orthopedics segment saw a 9.1% increase in sales to $3.0 billion, which beat analysts' expectations of $2.72 billion.
The company reported total revenue of $6.6 billion for the quarter, above analysts' expectations of $6.58 billion.
Stryker earned $3.69 per share for the quarter on an adjusted basis, surpassing estimates of $3.49 apiece.
However, the company's shares fell 9% in extended trading after the Michigan-based firm missed analysts' estimates for medical surgery and neurotechnology sales in the quarter, its largest revenue-generating segment.
Here are the details:
The company, which makes joint replacements and medical implants used to repair broken bones, narrowed its forecast for adjusted annual profit to between $14.95 and $15.10 per share, from its prior range of $14.90 to $15.10 per share.
Stryker's rivals in the orthopedics market include Zimmer Biomet (ZBH.N) and healthcare conglomerate Johnson & Johnson (JNJ.N), where the companies jostle for market share across multiple segments such as hip and knee replacements, trauma and sports medicine.
Sales at Stryker's medical surgery and neurotechnology unit, rose 9.7% to $3.6 billion in the reported quarter, but missed analysts' estimates of $3.72 billion, according to data compiled by LSEG.
The orthopedics segment saw a 9.1% increase in sales to $3.0 billion, which beat analysts' expectations of $2.72 billion.
The company reported total revenue of $6.6 billion for the quarter, above analysts' expectations of $6.58 billion.
Stryker earned $3.69 per share for the quarter on an adjusted basis, surpassing estimates of $3.49 apiece.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。